Antibodies floating on blue cell background - 3D illustration getty

In less than a decade, bispecific antibodies have gone from scientific curiosity to frontline cancer therapeutics. These engineered proteins, capable of binding to two or more targets simultaneously, are reshaping immunotherapy. They are also redrawing the competitive landscape of biopharma itself. With more than 2,000 clinical trials in oncology underway and U.S. cancer drug spending projected to hit $440 billion by 2029, the race is on to harness these molecules.

Five years ago, only a handful of patients had access to bispecific antibody therapies. Today, these drugs are rewriting treatment standards across some of the most challenging cancers. By directly bridging immune cells to tumors or blocking multiple

See Full Page